Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Research output: Contribution to journalArticlepeer-review

Standard

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. / Ahenkorah, Stephen; Cassells, Irwin; Deroose, Christophe; Cardinaels, Thomas; Burgoyne, Andrew; Bormans, Guy; Ooms, Maarten; Cleeren, Frederik.

In: Pharmaceutics, Vol. 13, No. 599, 599, 21.04.2021, p. 1-25.

Research output: Contribution to journalArticlepeer-review

Author

Ahenkorah, Stephen ; Cassells, Irwin ; Deroose, Christophe ; Cardinaels, Thomas ; Burgoyne, Andrew ; Bormans, Guy ; Ooms, Maarten ; Cleeren, Frederik. / Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. In: Pharmaceutics. 2021 ; Vol. 13, No. 599. pp. 1-25.

Bibtex - Download

@article{1c88044027f54b849c6e270f34f54e1d,
title = "Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside",
abstract = "In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.",
keywords = "Bismuth-213, Targeted Radionuclide Therapy, Targeted alpha therapy, Radiopharmaceutical, Bifunctional chelator, Vector molecule",
author = "Stephen Ahenkorah and Irwin Cassells and Christophe Deroose and Thomas Cardinaels and Andrew Burgoyne and Guy Bormans and Maarten Ooms and Frederik Cleeren",
note = "Score=10",
year = "2021",
month = apr,
day = "21",
doi = "10.3390/pharmaceutics13050599",
language = "English",
volume = "13",
pages = "1--25",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "MDPI",
number = "599",

}

RIS - Download

TY - JOUR

T1 - Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

AU - Ahenkorah, Stephen

AU - Cassells, Irwin

AU - Deroose, Christophe

AU - Cardinaels, Thomas

AU - Burgoyne, Andrew

AU - Bormans, Guy

AU - Ooms, Maarten

AU - Cleeren, Frederik

N1 - Score=10

PY - 2021/4/21

Y1 - 2021/4/21

N2 - In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

AB - In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

KW - Bismuth-213

KW - Targeted Radionuclide Therapy

KW - Targeted alpha therapy

KW - Radiopharmaceutical

KW - Bifunctional chelator

KW - Vector molecule

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/43457988

U2 - 10.3390/pharmaceutics13050599

DO - 10.3390/pharmaceutics13050599

M3 - Article

VL - 13

SP - 1

EP - 25

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 599

M1 - 599

ER -

ID: 7102090